Biodesix (BDSX)
(Delayed Data from NSDQ)
$1.80 USD
+0.01 (0.56%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $1.79 -0.01 (-0.56%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for Biodesix, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 49 | 38 | 55 | 46 | 25 |
Cost Of Goods | 13 | 14 | 31 | 22 | 6 |
Gross Profit | 36 | 24 | 24 | 24 | 18 |
Selling & Adminstrative & Depr. & Amort Expenses | 77 | 75 | 65 | 47 | 45 |
Income After Depreciation & Amortization | -41 | -51 | -41 | -23 | -27 |
Non-Operating Income | -1 | -7 | 2 | -1 | -1 |
Interest Expense | 10 | 8 | 5 | 8 | 3 |
Pretax Income | -52 | -65 | -43 | -31 | -31 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -52 | -65 | -43 | -31 | -31 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -52 | -65 | -43 | -31 | -31 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -31 | -40 | -35 | -16 | -24 |
Depreciation & Amortization (Cash Flow) | 11 | 11 | 6 | 7 | 3 |
Income After Depreciation & Amortization | -41 | -51 | -41 | -23 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 82.11 | 42.10 | 27.37 | 4.84 | NA |
Diluted EPS Before Non-Recurring Items | -0.62 | -1.38 | -1.64 | -6.48 | NA |
Diluted Net EPS (GAAP) | -0.64 | -1.55 | -1.58 | -6.48 | NA |
Fiscal Year end for Biodesix, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 17.93 | 14.82 | 14.67 | 13.49 | 11.87 |
Cost Of Goods | 3.88 | 3.18 | 3.37 | 3.23 | 3.24 |
Gross Profit | 14.05 | 11.64 | 11.29 | 10.26 | 8.63 |
SG&A, R&D, and Dept/Amort Expenses | 22.29 | 22.67 | 18.16 | 17.44 | 19.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.24 | -11.03 | -6.87 | -7.18 | -10.93 |
Non-Operating Income | -0.64 | -0.06 | 0.06 | -1.39 | 0.00 |
Interest Expense | 1.94 | 2.53 | 2.33 | 2.39 | 2.43 |
Pretax Income | -10.81 | -13.61 | -9.14 | -10.95 | -13.36 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.81 | -13.61 | -9.14 | -10.95 | -13.36 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -10.81 | -13.61 | -9.14 | -10.95 | -13.36 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 127.17 | 97.17 | 92.33 | 79.71 | 78.51 |
Diluted EPS Before Non-Recurring Items | -0.08 | -0.14 | -0.10 | -0.12 | -0.17 |
Diluted Net EPS (GAAP) | -0.08 | -0.14 | -0.09 | -0.14 | -0.17 |